Last updated: September 14, 2026
Cefadroxil is a mature, low-cost oral first-generation cephalosporin sold primarily as a generic antibiotic. Its commercial market is driven by prescription volume, hospital and retail formulary demand, supply reliability, and procurement pricing rather than patent exclusivity. Cefadroxil hemihydrate, often described in regulatory and product documentation through the active moiety cefadroxil or related hydrate terminology, does not have a meaningful remaining composition-of-matter patent barrier in the United States.
The product has limited standalone revenue disclosure because manufacturers generally report cefadroxil within broader generic portfolios. Its financial trajectory is likely characterized by long-term unit demand, declining or stable nominal prices, low gross margins, periodic price increases during supply disruptions, and continued erosion from competition among generic manufacturers.
What is cefadroxil and how is cefadroxil hemihydrate used?
Cefadroxil is an orally administered first-generation cephalosporin antibacterial. It inhibits bacterial cell-wall synthesis and is used for susceptible infections, including skin and skin-structure infections, urinary tract infections, and upper respiratory tract infections when the causative organism is susceptible. The FDA label identifies cefadroxil as the active antibacterial ingredient and provides capsule, tablet, and oral suspension dosage forms. [1]
Cefadroxil products are commonly marketed in strengths including:
| Dosage form |
Common strength |
| Capsules |
500 mg |
| Tablets |
1 g |
| Oral suspension |
250 mg/5 mL |
| Oral suspension |
500 mg/5 mL |
The commercial product may use a hydrate form of cefadroxil to support manufacturing and stability. Regulatory products are generally labeled by cefadroxil equivalent rather than by a separate commercial category for “cefadroxil hemihydrate.” This distinction matters for chemical manufacturing and specification control, but it does not normally create a separate clinical market.
What is the FDA regulatory status of cefadroxil?
Cefadroxil is an established FDA-approved small-molecule antibiotic. FDA-approved products are available through abbreviated new drug applications, or ANDAs, that demonstrate pharmaceutical equivalence and bioequivalence to the reference product. [2]
The original branded product, Duricef, was approved decades ago. Its principal market protections have expired. Current commercial activity is therefore concentrated in generic prescription products rather than an actively promoted branded product.
FDA regulatory characteristics
| Regulatory element |
Cefadroxil status |
| Drug class |
First-generation cephalosporin |
| Route |
Oral |
| FDA pathway for current competitors |
ANDA |
| Reference product |
Duricef and related historical reference products |
| New chemical entity exclusivity |
Expired |
| Pediatric exclusivity |
Not commercially relevant to current competition |
| Orphan exclusivity |
Not applicable |
| Biosimilar pathway |
Not applicable |
| Current market structure |
Generic multi-source market |
The FDA label includes warnings concerning beta-lactam hypersensitivity, Clostridioides difficile-associated diarrhea, and the need to select therapy based on susceptibility and clinical indications. [1]
What patents protect cefadroxil and cefadroxil hemihydrate?
No commercially meaningful active U.S. patent estate is generally associated with cefadroxil as a mature generic active pharmaceutical ingredient. The original compound and early product technology date from the pre-generic era, and the relevant patent terms expired many years ago.
The remaining intellectual-property issues are more likely to involve manufacturing know-how, crystallization, impurity control, formulation process parameters, packaging, or supplier-specific documentation than enforceable exclusivity over cefadroxil itself.
| Patent category |
Commercial relevance |
| Original cefadroxil compound patent |
Expired |
| Original product patent |
Expired |
| Basic oral formulation patent |
Expired or no longer commercially material |
| Method-of-use patent |
No material current barrier identified for established indications |
| Cefadroxil hemihydrate composition patent |
No meaningful market-blocking estate generally recognized |
| Manufacturing process patent |
Potentially relevant to individual suppliers |
| Trade secret and know-how |
Relevant to yield, impurity profile, and cost |
| Packaging or device patent |
Limited relevance for capsules, tablets, and suspension |
The Orange Book is relevant to listed patents and exclusivity for approved drug products. For a mature multi-source antibiotic such as cefadroxil, the key commercial conclusion is the absence of a current patent-based barrier to ANDA competition. FDA Orange Book records should be reviewed at the individual product level because listings can vary by sponsor, dosage form, and application history. [3]
When did cefadroxil lose exclusivity?
Cefadroxil lost meaningful market exclusivity decades ago. The product is now in the mature generic phase of its lifecycle.
Cefadroxil exclusivity timeline
| Period |
Commercial event |
| 1970s |
Original branded cefadroxil products introduced and approved |
| 1980s and 1990s |
Patent and branded-product protections expired; generic entry expanded |
| 2000s |
Multi-source generic supply became established |
| 2010s |
Retail and institutional pricing became increasingly procurement-driven |
| 2020-2024 |
Market remained mature, with supply-chain and API availability affecting pricing |
Unlike newer antibiotics, cefadroxil has no remaining period of new-drug exclusivity that would prevent generic entry. There is no current market rationale for a successful Paragraph IV strategy directed at the original cefadroxil molecule unless a specific later-listed patent were identified for an individual product.
How many patents cover cefadroxil?
The practical answer is that no active U.S. patent portfolio appears to control the core cefadroxil market. Historical patents may exist in global patent databases, and individual manufacturers may hold process or formulation rights, but those rights do not appear to create broad market exclusivity.
A patent landscape for cefadroxil should distinguish four categories:
- Expired compound and product patents.
- Expired formulation and dosage-form patents.
- Potentially active process patents held by API or finished-dose manufacturers.
- Non-patent manufacturing know-how, including crystallization, drying, impurity removal, and suspension stability.
Process patents can affect the cost or legality of a particular manufacturing route without preventing competitors from selling cefadroxil manufactured through another route. This limits their ability to support premium pricing.
What formulations are protected by cefadroxil patents?
The commercially important formulations are immediate-release capsules, tablets, and oral suspensions. These dosage forms are technically established and generally reproducible by generic manufacturers.
Formulation economics
Capsules and tablets have relatively low manufacturing complexity. Oral suspension has greater operational requirements because manufacturers must control particle size, sedimentation, redispersibility, preservative performance, taste, reconstitution instructions, and stability after reconstitution.
The suspension segment can therefore have higher entry and supply-chain friction than solid oral dosage forms. That friction is a manufacturing barrier, not necessarily a patent barrier.
| Formulation |
Market characteristics |
Relative entry difficulty |
| 500 mg capsule |
High manufacturability; retail and institutional demand |
Low |
| 1 g tablet |
Lower volume than capsules in some channels; straightforward production |
Low |
| 250 mg/5 mL suspension |
Pediatric and outpatient use; stability and taste requirements |
Moderate |
| 500 mg/5 mL suspension |
Similar suspension controls; lower supplier breadth in some markets |
Moderate |
No broadly enforceable formulation patent is generally recognized as protecting these dosage forms in the current U.S. market.
What is the Orange Book status of cefadroxil?
The Orange Book provides product-specific information for FDA-approved drug applications, including reference-listed drugs, therapeutically equivalent products, patents, and exclusivity. [3]
For cefadroxil, the Orange Book’s commercial significance is limited because the product is a mature generic antibiotic. The principal questions are:
- Whether a particular application is listed as a reference product or generic product.
- Whether any patent is listed against a specific application.
- Whether therapeutic-equivalence codes support automatic substitution under state pharmacy rules.
- Whether a product has been discontinued or remains actively marketed.
A generic manufacturer evaluating entry should review current Orange Book listings, FDA application status, product marketing status, and therapeutic-equivalence data for each strength and dosage form. Historical approval does not guarantee current commercial availability.
Which companies compete in the cefadroxil market?
Cefadroxil is supplied by a changing group of generic manufacturers, contract manufacturers, distributors, and private-label suppliers. Market participation varies by country and by dosage form.
In the United States, generic antibiotics may be marketed by large generic companies, specialty generic firms, and distributor-linked labels. The same finished product may be manufactured by one company and distributed under another company’s label. This makes label count an imperfect measure of manufacturing competition.
Competitive variables include:
- API sourcing and qualification.
- FDA manufacturing compliance.
- Finished-dose capacity.
- Supply reliability.
- Wholesale acquisition price.
- Group purchasing organization contracts.
- Retail pharmacy distribution.
- Suspension manufacturing capacity.
- Product discontinuation decisions.
The market is more fragmented than the branded-antibiotic market, but it is not necessarily fully commoditized. A manufacturer with reliable API access and uninterrupted finished-dose supply can gain share during shortages or competitor exits.
How strong is the cefadroxil patent estate?
The patent estate is weak from a market-exclusivity perspective. Its commercial strength is low because:
- The active molecule is old.
- Core product patents have expired.
- Multiple generic manufacturers can produce the product.
- The principal dosage forms use established technology.
- No biosimilar pathway or biologic manufacturing barrier applies.
- Buyers usually prioritize price, availability, and approved supplier status.
The more relevant protection is operational. A supplier may have advantages in API yield, impurity management, regulatory documentation, and validated manufacturing capacity. These advantages can produce temporary commercial differentiation but are difficult to enforce as long-term exclusivity.
Are there Paragraph IV challenges or cefadroxil patent lawsuits?
Cefadroxil is unlikely to generate significant current Paragraph IV litigation because the original patent estate has expired and the drug has been generic for decades. Paragraph IV certifications are most commercially significant when a generic applicant challenges a listed patent before expiration. That framework has limited relevance to an old product without a meaningful current patent barrier.
No major recent branded-versus-generic cefadroxil patent dispute is generally associated with the core product market. Litigation risk is more likely to arise from:
- ANDA product-liability claims.
- Manufacturing and quality disputes.
- Contract disputes involving API or finished-dose supply.
- False advertising or distribution issues.
- Antitrust claims involving generic supply or pricing.
- Patent disputes involving a particular manufacturing process.
The absence of core patent litigation does not eliminate regulatory risk. FDA action against a manufacturing site, import alert, warning letter, or product recall can materially change market share.
What generic entry risks exist for cefadroxil?
Generic entry risk is high because entry barriers are low and exclusivity is absent. The risk is greatest for suppliers that compete only on price and lack dependable API or finished-dose capacity.
Entry-risk assessment
| Risk factor |
Assessment |
| Patent barrier |
Low |
| Regulatory pathway |
Established ANDA pathway |
| Formulation complexity |
Low for solids; moderate for suspension |
| API availability |
Important cost and continuity variable |
| Switching friction |
Low for approved equivalent products |
| Pricing pressure |
High |
| Substitution risk |
High across generic suppliers |
| Supply disruption upside |
Temporary and opportunity-driven |
| Long-term differentiation |
Limited |
Generic entrants can reduce prices rapidly when several approved suppliers are active. Conversely, shortages can produce temporary pricing power if the number of qualified suppliers falls.
What are the market dynamics for cefadroxil?
Cefadroxil demand is relatively stable but not immune to clinical substitution. Physicians may choose other first-generation cephalosporins, penicillins, macrolides, or newer agents depending on infection type, allergy history, local resistance patterns, dosing preferences, and stewardship policies.
The main market drivers are:
- Persistent demand for inexpensive oral antibiotics.
- Use in outpatient infections and selected urinary or skin infections.
- Generic substitution and formulary placement.
- Procurement concentration among wholesalers and institutions.
- API and finished-dose manufacturing continuity.
- Antibiotic stewardship and resistance management.
- Seasonal changes in pediatric and respiratory prescribing.
Cefadroxil does not have the growth profile of a novel anti-infective. Its volume outlook is mature, and revenue expansion is more likely to come from price changes, supply shortages, market-share gains, or geographic expansion than from underlying therapeutic growth.
What is the financial trajectory of cefadroxil?
No reliable public source reports global cefadroxil revenue as a standalone product across all manufacturers. Generic companies typically combine cefadroxil revenue with broader oral antibiotics or generic portfolio revenue.
The most defensible financial trajectory is:
| Lifecycle phase |
Revenue pattern |
Margin pattern |
| Branded launch |
High price and concentrated sales |
High |
| Early generic entry |
Rapid price erosion |
Declining |
| Mature generic market |
Stable or declining nominal revenue |
Low to moderate |
| Supply disruption |
Temporary price and revenue increase |
Potentially higher |
| Re-entry or supplier exit |
Share shifts among remaining suppliers |
Variable |
Unit demand can remain durable while revenue falls because average selling prices decline. A manufacturer may generate acceptable returns if it has low-cost API supply, high plant utilization, and efficient regulatory maintenance. A manufacturer with higher production costs may exit despite continuing demand.
Revenue exposure
Cefadroxil is unlikely to be a material revenue driver for diversified pharmaceutical companies. It can be strategically relevant for:
- Generic manufacturers with established oral-solid capacity.
- Antibiotic-focused contract manufacturers.
- API producers.
- Regional distributors.
- Suppliers serving government or hospital tenders.
- Companies expanding into emerging markets where oral first-generation cephalosporins remain widely used.
Revenue concentration risk is usually low for a diversified company but can be high for a small supplier whose antibiotic portfolio depends on a limited number of products.
How does cefadroxil compare with cephalexin?
Cefadroxil competes most directly with cephalexin, another oral first-generation cephalosporin. Both are mature generics with extensive clinical familiarity and limited patent protection.
| Factor |
Cefadroxil |
Cephalexin |
| Drug class |
First-generation cephalosporin |
First-generation cephalosporin |
| Administration |
Oral |
Oral |
| Dosing convenience |
Often longer dosing interval depending on indication |
Often more frequent dosing |
| Generic competition |
High |
High |
| Patent protection |
Expired |
Expired |
| Commercial positioning |
Lower-volume mature generic |
Broader and often larger generic market |
| Key differentiation |
Dosing convenience and supplier availability |
Established utilization and broad availability |
Cephalexin generally has greater market visibility and broader generic penetration. Cefadroxil can compete through dosing convenience, specific formulary preferences, and reliable supply, but it has limited pricing power.
What manufacturing and geographic barriers affect cefadroxil?
The main geographic issue is the separation between API production and finished-dose markets. Cefadroxil may be manufactured in one country, formulated in another, and distributed through a third-party labeler.
Important geographic barriers include:
- FDA, European Medicines Agency, and national GMP requirements.
- Import controls and inspection outcomes.
- API source qualification.
- Country-specific registration requirements.
- Local bioequivalence documentation.
- Tender-based procurement.
- Currency fluctuations.
- Shipping and inventory costs.
- Regional differences in antibiotic prescribing.
In emerging markets, cefadroxil may have broader availability through local manufacturers and branded generics. In highly regulated markets, supplier qualification and manufacturing compliance can be more important than patent ownership.
What licensing deals and settlement agreements affect cefadroxil?
No major current licensing deal or commercial settlement is generally associated with the core cefadroxil market. The original branded rights are historical, and current products are commonly supplied through generic manufacturing, distribution, or contract-manufacturing arrangements.
Relevant commercial agreements are more likely to involve:
- API supply contracts.
- Contract development and manufacturing agreements.
- Private-label distribution.
- Regional marketing rights.
- Hospital and government tenders.
- Authorized generic supply arrangements.
These agreements can change market share without changing the underlying patent position.
Key Takeaways
- Cefadroxil and cefadroxil hemihydrate are mature generic antibiotic products with no meaningful core patent barrier in the United States.
- FDA exclusivity and original branded protections expired decades ago.
- The market includes capsules, tablets, and oral suspensions, with suspension manufacturing somewhat more complex.
- Paragraph IV and branded patent-litigation risk is low for the core product.
- Biosimilar risk does not apply because cefadroxil is a small molecule, not a biologic.
- Financial performance depends on volume, procurement pricing, API costs, plant utilization, and supply continuity.
- Standalone global revenue is not publicly consolidated across manufacturers.
- Cefadroxil competes most directly with cephalexin and other low-cost oral antibiotics.
- Manufacturing know-how, supplier qualification, and regulatory compliance are more important than patent ownership.
- The strongest commercial opportunity is temporary share capture during supplier exits or shortages, not long-term premium pricing.
FAQs About Cefadroxil Market and Patent Risk
Is cefadroxil still protected by a U.S. patent?
No meaningful patent protection over the cefadroxil molecule or standard commercial dosage forms remains in force for the mature U.S. generic market.
Is cefadroxil hemihydrate a separate FDA-approved drug?
Regulatory products are generally identified by cefadroxil and cefadroxil equivalent. The hydrate form is primarily a chemical and manufacturing specification rather than a separate therapeutic market.
Can a company launch a new generic cefadroxil product?
Yes. A company can pursue an ANDA for an approved dosage form, subject to FDA requirements for pharmaceutical equivalence, bioequivalence, manufacturing quality, labeling, and facility compliance.
Does cefadroxil have biosimilar competition?
No. Biosimilars apply to biological products. Cefadroxil is a conventional small-molecule drug and competes through generic approval pathways.
What could increase cefadroxil pricing?
Pricing could rise temporarily if API shortages, manufacturing failures, regulatory actions, recalls, or supplier exits reduce the number of qualified competitors. Sustained premium pricing is unlikely without a significant supply constraint.
References
-
U.S. Food and Drug Administration. (2019). Cefadroxil: Prescribing information. FDA/DailyMed labeling.
-
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application (ANDA) process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
World Health Organization. (2023). The WHO AWaRe antibiotic book: Antibiotic book. World Health Organization.
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
